Aclarion Inc. has appointed Greg Gould as its new chief financial officer, effective immediately. Gould comes to Aclarion with more than 30 years of experience in public and private companies.
He succeeds John Lorbiecki, who has announced his retirement after establishing a strong financial foundation for the company, Aclarion stated in a press release. Aclarion CEO Brent Ness expressed enthusiasm for Gould’s expertise in capital strategies and financial leadership, which they believe will support the company’s vision of expanding its healthcare technology for chronic low back pain.
Gould has successfully raised over $450 million in public company funding, led numerous acquisitions, and guided companies through uplistings to Nasdaq. His most recent role was CFO at Nanos Health, a startup focused on nanotechnology in drug delivery. He has also served as CFO for seven publicly traded companies.
In his statement, Gould highlighted the potential of Aclarion’s innovative technology to improve care for millions suffering from chronic low back pain, stating, “The chance to build on the company’s recent momentum and help scale the business is incredibly compelling.”
The appointment comes as Broomfield-based Aclarion continues to address the global challenge of chronic low back pain, which affects approximately 266 million people worldwide. The company’s solution aims to help physicians better identify pain-related issues in the lumbar spine, potentially improving surgical outcomes.
